What are the main obstacles in oncology market access, Ed Schoonveld?

Klicken Sie auf den unteren Button, um den Inhalt von player.captivate.fm zu laden.

Inhalt laden

Companies launching oncology drugs sometimes struggle with existing reimbursement pathways and negotiations with payers, mainly in Europe, but also in other parts of the world. Evidence generation is the start of every drug development, but especially in oncology the design is important – not only that payers want to get a proof of a longer survival, but they also have further needs in their internal assessment. Enjoy the insights shared by the oncology market access veterans Dr. Stefan Walzer and Ed Schoonveld. 


Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de


#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #Europe #oncology